Integrin Targeting for Tumor Optical Imaging
Open accessThe DOI matches its Crossref record.
Abstract
Optical imaging has emerged as a powerful modality for studying molecular recognitions and molecular imaging in a noninvasive, sensitive, and real-time way. Some advantages of optical imaging include cost-effectiveness, convenience, and non-ionization safety as well as complementation with other imaging modalities such as positron emission tomography (PET), single-photon emission computed tomography (SPECT), and magnetic resonance imaging (MRI). Over the past decade, considerable advances have been made in tumor optical imaging by targeting integrin receptors in preclinical studies. This review has emphasized the construction and evaluation of diverse integrin targeting agents for optical imaging of tumors in mouse models. They mainly include some near-infrared fluorescent dye-RGD peptide conjugates, their multivalent analogs, and nanoparticle conjugates for targeting integrin αvβ3. Some compounds targeting other integrin subtypes such as α4β1 and α3 for tumor optical imaging have also been included. Both in vitro and in vivo studies have revealed some promising integrin-targeting optical agents which have further enhanced our understanding of integrin expression and targeting in cancer biology as well as related anticancer drug discovery. Especially, some integrin-targeted multifunctional optical agents including nanoparticle-based optical agents can multiplex optical imaging with other imaging modalities and targeted therapy, serving as an attractive type of theranostics for simultaneous imaging and targeted therapy. Continued efforts to discover and develop novel, innovative integrin-based optical agents with improved targeting specificity and imaging sensitivity hold great promises for improving cancer early detection, diagnosis, and targeted therapy in clinic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Liposomes as nanomedical devices
Bozzuto, G., & Molinari, A. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s68861 · Cited by 2,261
RGD-Based Strategies To Target Alpha(v) Beta(3) Integrin in Cancer Therapy and Diagnosis
Danhier, F., Le Breton, A., & Préat, V. (2012) · Molecular Pharmaceutics · doi:10.1021/mp3002733 · Cited by 955
Muthu, M. S., Leong, D. T., Mei, L., & Feng, S.-S. (2014) · Theranostics · doi:10.7150/thno.8698 · Cited by 603
Targeted zwitterionic near-infrared fluorophores for improved optical imaging
Choi, H. S., Gibbs, S. L., Lee, J. H., Kim, S. H., Ashitate, Y., Liu, F., Hyun, H., Park, G., Xie, Y., Bae, S., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2468 · Cited by 560
Structural and functional photoacoustic molecular tomography aided by emerging contrast agents
Nie, L., & Chen, X. (2014) · Chem. Soc. Rev. · doi:10.1039/c4cs00086b · Cited by 383
Self-citationRGD-Modified Apoferritin Nanoparticles for Efficient Drug Delivery to Tumors
Zhen, Z., Tang, W., Chen, H., Lin, X., Todd, T., Wang, G., Cowger, T., Chen, X., & Xie, J. (2013) · ACS Nano · doi:10.1021/nn305791q · Cited by 368
Self-citationPhotodynamic nanomedicine in the treatment of solid tumors: Perspectives and challenges
Master, A., Livingston, M., & Sen Gupta, A. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.02.020 · Cited by 367
Chi, C., Du, Y., Ye, J., Kou, D., Qiu, J., Wang, J., Tian, J., & Chen, X. (2014) · Theranostics · doi:10.7150/thno.9899 · Cited by 358
Self-citationNear-infrared (NIR) fluorescence-emitting small organic molecules for cancer imaging and therapy
Li, H., Kim, Y., Jung, H., Hyun, J. Y., & Shin, I. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00722c · Cited by 356
Nanoparticles for multimodal in vivo imaging in nanomedicine
Leary, J., & Key, J. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s53717 · Cited by 300
Clinical Application of Radiolabeled RGD Peptides for PET Imaging of Integrin αvβ3
Chen, H., Niu, G., Wu, H., & Chen, X. (2016) · Theranostics · doi:10.7150/thno.13242 · Cited by 282
Self-citationReissmann, S. (2014) · Journal of Peptide Science · doi:10.1002/psc.2672 · Cited by 266
Immune determinants of the pre-metastatic niche
Patras, L., Shaashua, L., Matei, I., & Lyden, D. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.02.018 · Cited by 221
A Targeting Nanotherapy for Abdominal Aortic Aneurysms
Cheng, J., Zhang, R., Li, C., Tao, H., Dou, Y., Wang, Y., Hu, H., & Zhang, J. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.08.2188 · Cited by 109
Facciolà, A., Visalli, G., La Maestra, S., Ceccarelli, M., D’Aleo, F., Nunnari, G., Pellicanò, G. F., & Di Pietro, A. (2019) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2018.11.006 · Cited by 84
Yue, N.-N., Xu, H.-M., Xu, J., Zhu, M.-Z., Zhang, Y., Tian, C.-M., Nie, Y.-Q., Yao, J., Liang, Y.-J., Li, D.-F., et al. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s413141 · Cited by 46
Qi, B., Crawford, A. J., Wojtynek, N. E., Talmon, G. A., Hollingsworth, M. A., Ly, Q. P., & Mohs, A. M. (2020) · Theranostics · doi:10.7150/thno.40688 · Cited by 18
“membranes, pharmacokinetic processes, including absorption, distribution, metabolism and excretion, and optical properties of the dye and tissue [12].”
Metadata
- Authors
- Ye, Y., & Chen, X.
- Venue
- Theranostics
- Publisher
- Ivyspring International Publisher
- Published
- 2011
- Volume
- 1
- Pages
- 102-126
- ISSN
- 1838-7640 (ISSN-L)
- OpenAlex
- W2100236235
- Cited by
- 153
- References
- 0
- FWCI
- 10.94
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.